Literature DB >> 26517228

Survival Impact of Pulmonary Metastasis as Recurrence of Pancreatic Ductal Adenocarcinoma.

Kotaro Yamashita1, Atsushi Miyamoto, Naoki Hama, Tadafumi Asaoka, Sakae Maeda, Hideyasu Omiya, Koji Takami, Yuichiro Doki, Masaki Mori, Shoji Nakamori.   

Abstract

AIM: This study aimed at investigating the survival impact of pancreatic ductal adenocarcinoma (PDAC) recurrence as pulmonary metastasis.
METHODS: We performed a retrospective case-control study of 142 patients who underwent curative resection for PDAC at our institution between 2003 and 2012. Clinicopathological features were compared among patients stratified according to the recurrence pattern and pulmonary metastasis treatment strategy.
RESULTS: Patients underwent pancreaticoduodenectomy (n = 96), distal (n = 42), or total pancreatectomy (n = 4). At the last follow-up, 99 patients had developed recurrent post-resection PDAC, including 14 cases of isolated pulmonary recurrence. The median overall survival was significantly longer for patients with isolated pulmonary recurrence (40.3 months) than with other metastases (20.9 months; HR 5.85; p = 0.0156). Two patients underwent resection for isolated pulmonary recurrence, and both survived for ∼70 months after primary resection.
CONCLUSION: Patients with first recurrence of PDAC as pulmonary metastasis had a better prognosis than patients with other types of metastases. Moreover, when isolated pulmonary metastasis is controlled for a certain period, pulmonary resection is likely to improve patient survival.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2015        PMID: 26517228     DOI: 10.1159/000439545

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  12 in total

1.  Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.

Authors:  Kenji Nakagawa; Takahiro Akahori; Satoshi Nishiwada; Minako Nagai; Kota Nakamura; Toshihiro Tanaka; Tetsuro Tamamoto; Chiho Ohbayashi; Masatoshi Hasegawa; Kimihiko Kichikawa; Naoya Ikeda; Masayuki Sho
Journal:  Langenbecks Arch Surg       Date:  2018-09-15       Impact factor: 3.445

2.  Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.

Authors:  Lei Miao; Jingjing Li; Qi Liu; Richard Feng; Manisit Das; C Michael Lin; Tyler J Goodwin; Oleksandra Dorosheva; Rihe Liu; Leaf Huang
Journal:  ACS Nano       Date:  2017-08-28       Impact factor: 15.881

3.  Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer.

Authors:  Maximilian Reichert; Basil Bakir; Leticia Moreira; Jason R Pitarresi; Karin Feldmann; Lauren Simon; Kensuke Suzuki; Ravikanth Maddipati; Andrew D Rhim; Anna M Schlitter; Mark Kriegsmann; Wilko Weichert; Matthias Wirth; Kathleen Schuck; Günter Schneider; Dieter Saur; Albert B Reynolds; Andres J Klein-Szanto; Burcin Pehlivanoglu; Bahar Memis; N Volkan Adsay; Anil K Rustgi
Journal:  Dev Cell       Date:  2018-06-18       Impact factor: 12.270

4.  Long-term survival after repeated resection of metachronous lung metastases from pStage IA pancreatic adenocarcinoma.

Authors:  Mamoru Miyasaka; Takehiro Noji; Kazuto Ohtaka; Ryohei Chiba; Shoki Sato; Yasuhito Shoji; Ryunosuke Hase; Tatsunosuke Ichimura; Satoshi Hirano; Naoto Senmaru
Journal:  Clin J Gastroenterol       Date:  2017-10-16

5.  Integrative analysis identifies activated anti-tumor immune microenvironment in lung metastasis of pancreatic cancer.

Authors:  Toshihide Sasaki; Satoshi Nishiwada; Kenji Nakagawa; Minako Nagai; Taichi Terai; Daisuke Hokuto; Satoshi Yasuda; Yasuko Matsuo; Shunsuke Doi; Masayuki Sho
Journal:  Int J Clin Oncol       Date:  2022-02-10       Impact factor: 3.402

6.  FOLFIRINOX in patients with peritoneal carcinomatosis from pancreatic adenocarcinoma: a retrospective study.

Authors:  E Bonnet; C Mastier; A Lardy-Cléaud; P Rochefort; M Sarabi; P Guibert; A Cattey-Javouhey; F Desseigne; C de La Fouchardière
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

7.  Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Ding Ding; Ammar A Javed; Richard A Burkhart; Jun Yu; Inne H Borel Rinkes; I Quintus Molenaar; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg Oncol       Date:  2018-06-14       Impact factor: 5.344

Review 8.  Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.

Authors:  Martin Lovecek; Pavel Skalicky; Josef Chudacek; Marek Szkorupa; Hana Svebisova; Radmila Lemstrova; Jiri Ehrmann; Bohuslav Melichar; Tharani Yogeswara; Dusan Klos; Radek Vrba; Roman Havlik; Beatrice Mohelnikova-Duchonova
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

9.  Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report.

Authors:  Ryota Matsuki; Masanori Sugiyama; Hidefumi Takei; Haruhiko Kondo; Masachika Fujiwara; Junji Shibahara; Junji Furuse
Journal:  Surg Case Rep       Date:  2018-03-27

10.  Lung Metastases in Patients with Stage IV Pancreatic Cancer: Prevalence, Risk Factors, and Survival Impact.

Authors:  Keng-Hao Liu; Chia-Yen Hung; Shu-Wen Hsueh; Pei-Hung Chang; Yen-Yang Chen; Chang-Hsien Lu; Ping-Tsung Chen; Kun-Yun Yeh; Pei-Wei Huang; Ngan-Ming Tsang; Yu-Shin Hung; Wen-Chi Chou
Journal:  J Clin Med       Date:  2019-09-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.